Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

Launched by ASTRAZENECA · Oct 30, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus," is looking to understand how well the medication anifrolumab works for patients with systemic lupus erythematosus (SLE) in everyday treatment settings. It is being conducted in multiple centers across Poland and aims to gather information about patients' experiences and health outcomes after receiving this treatment.

To be part of the study, potential participants must be adults aged 18 or older who have been treated with anifrolumab in Poland. They should also be willing to participate and provide consent for the study. However, individuals who have taken part in a clinical trial for anifrolumab in the past, or who have difficulty understanding or cooperating due to cognitive issues or language barriers, are not eligible. Participants can expect to share their treatment experiences and outcomes, which will help researchers understand the effectiveness of anifrolumab in managing lupus. This study is currently recruiting participants, and your involvement can contribute to valuable insights in lupus treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult (aged ≥18 years old) patients with SLE who received anifrolumab treatment in the frames of NDP in Poland.
• • 2. Patients willing to participate in the study and signed Informed Consent Form (ICF).
• Exclusion Criteria:
• • 1. Those who participated in anifrolumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first anifrolumab infusion through NDP.
• • 2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.